GMED Stock Analysis: Buy, Sell, or Hold?
GMED - GLOBUS MEDICAL INC
$76.64
0.44 (0.58%)
▲
5d:
+0.9%
30d:
-2.12%
90d:
-16.66%
HOLD
MODERATE Confidence
Analysis Updated: Jul 9, 2026 12:00 AM ET
Earnings: Aug 06, 2026
26d
Get Alerted When GMED Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
1 traders called GMED this week
100% bullish • 0 bearish
100% bullish • 0 bearish
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: GMED shows mixed signals. Fine to hold existing positions. Not urgent to buy or sell.
📊 HOLD: GMED shows mixed signals. Fine to hold existing positions. Not urgent to buy or sell.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$130.22
Based on 6.3% avg growth
INTRINSIC VALUE TODAY
$80.85
5.2% Margin of Safety
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 18.7x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: GMED is currently trading at $76.64, which is considered oversold relative to its 30-day fair value range of $77.13 to $82.24. From a valuation perspective, the stock is trading at a discount (Forward PE: 14.9) compared to its historical average (18.7). Remarkably, the market is currently pricing in an annual earnings decline of 7.3% over the next few years. This pessimistic expectation contrasts with the company's recent 66.7% earnings growth, suggesting potential undervaluation if the company simply maintains stability.
Technical Outlook: Technically, GMED is in a strong downtrend. The price is currently testing key support at $74.94. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: GMED has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Wall Street analysts see significant upside, with an average price target of $108.64 (+41.7%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, GMED is in a strong downtrend. The price is currently testing key support at $74.94. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: GMED has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Wall Street analysts see significant upside, with an average price target of $108.64 (+41.7%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$77.13 -
$82.24
Company Quality Score
54/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
57.1%
Protect Your Profits
Holding GMED? Use our AI-powered strategies to protect your downside while keeping your long-term position.
View Profit Protection PlanAll Signals
- BULLISH: Price oversold vs 30-day range
- BEARISH: Weak technical setup (25/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 41.7% below Wall St target ($108.64)
Trading Range Analysis
30-Day Trading Range
$77.13 -
$82.24
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$74.95
Resistance Level
$86.34
Current Trend
Strong Downtrend
Technical data as of
Jul 9, 2026
Fundamental Context
Forward P/E (Next Year Est.)
14.89
Wall Street Target
$108.64
(+41.7%)
Revenue Growth (YoY)
27.0%
Earnings Growth (YoY)
66.7%
Profit Margin
18.9%
Valuation Discount vs History
-7.3% cheaper
PE vs Historical
14.9 vs 18.7
CHEAP
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-7.3%
(market-implied from PE analysis)
1-Year Target
$71.05
(-7%)
2-Year Target
$65.86
(-14%)
3-Year Target
$61.05
(-20%)
3-Yr Target (if PE normalizes)
(PE: 15→19)
$76.65
(0%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 21.8, Growth: 8.5%)
$143.07
(+87%)
Base:
(SPY PE: 14.9, Growth: 8.5%)
$97.84
(+28%)
Bear:
(PE: 12.7, Growth: 8.5%)
$83.17
(+9%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (18x PE), but valuation improves significantly next year (15x PE) as earnings recover.
Trailing PE: 18.41 | Current EPS (TTM): $4.14
Bull Case
$104.18
(+36%)
Analyst growth 24.3%, PE expands to 20.3
Base Case
$94.71
(+24%)
Market implied 24.3%, PE stable at 18.4
Bear Case
$51.82
(-32%)
Severe decline -20.0%, PE contracts to 15.6
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 14.9 to 18.7
Stabilization Target:
$96.22
(+25.5%)
PE Expansion Potential:
+25.5%
Share & Embed Analysis
Last updated: July 10, 2026 8:31 AM ET
Data refreshes hourly during market hours. Next update: 9:31 AM
Data refreshes hourly during market hours. Next update: 9:31 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is GMED showing a specific setup today?
Insider Activity (6 Months)
1
Buys
2
Sells
Net
INSIDERS SELLING
Recent Transactions
Gilbert Ray Cisneros, Jr.
BUY
2026-03-03
Kelly Huller
SELL
20000 shares
2026-02-25
Kelly Huller
SELL
10000 shares
2026-02-12
Top Rated Medical Devices Stocks
Top-rated stocks in Medical Devices by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BSX
Boston Scientific Corp |
STRONG BUY
34 analysts |
$75 | 65 BUY |
|
DXCM
DexCom Inc |
STRONG BUY
27 analysts |
$85 | 65 BUY |
|
ABT
Abbott Laboratories |
STRONG BUY
27 analysts |
$117 | 64 BUY |
|
MDT
Medtronic PLC |
BUY
32 analysts |
$98 | 65 BUY |
|
PODD
Insulet Corporation |
STRONG BUY
24 analysts |
$240 | 59 HOLD |
Advanced GMED Option Strategies
Professional options setups generated by AI based on today's GMED price and gamma walls.
